within Pharmacolibrary.Drugs.ATC.R;

model R03AK14
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00038833333333333336,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 2.38,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 3.8,
    k12             = 36.3,
    k21             = 36.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AK14</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Indacaterol and mometasone is a fixed-dose combination medication containing indacaterol, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, an inhaled corticosteroid (ICS). It is used for the maintenance treatment of asthma in adults and adolescents. The combination provides bronchodilation and anti-inflammatory effects, and is approved in several countries for asthma management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated based on the known pharmacokinetic properties of indacaterol and mometasone furoate in healthy adults following inhalation; fixed-dose combination pharmacokinetics are assumed to be additive of the single components.</p><h4>References</h4><ol><li><p>Vaidya, S, et al., &amp; Tillmann, HC (2020). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. <i>Pulmonary pharmacology &amp; therapeutics</i> 64 101964–None. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2020.101964&quot;>10.1016/j.pupt.2020.101964</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33035700/&quot;>https://pubmed.ncbi.nlm.nih.gov/33035700</a></p></li><li><p>Vaidya, SS, et al., &amp; Woessner, R (2016). Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects. <i>Pulmonary pharmacology &amp; therapeutics</i> 37 30–36. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2016.01.004&quot;>10.1016/j.pupt.2016.01.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26845343/&quot;>https://pubmed.ncbi.nlm.nih.gov/26845343</a></p></li><li><p>Vaidya, SS, et al., &amp; Kaiser, G (2016). Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 5(4) 285–295. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.245&quot;>10.1002/cpdd.245</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27310329/&quot;>https://pubmed.ncbi.nlm.nih.gov/27310329</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AK14;
